Traws Pharma Inc expected to post a loss of 34 cents a share - Earnings Preview
Traws Pharma Inc <TRAW.OQ> expected to post a loss of 34 cents a share - Earnings Preview
Traws Pharma Inc TRAW.OQ TRAW.O is expected to report resultson August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Traws Pharma Inc is for a loss of 34 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Traws Pharma Inc is $1.00, about 88% above its last closing price of $0.53
This summary was machine generated August 10 at 13:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Traws Pharma
See all newsBrief: Traws Pharma - Enters Stock Purchase Agreement With Roth Principal Investments On Oct 23, 2026 - SEC Filing
Traws Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens
Traws Pharma Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Traws Pharma Provides Updated Guidance On Influenza Prophylaxis Program